

Table 1. Five-Year Relative Survival*, All Cancer Sites Combined, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

All Cancer Sites Combined												
All Races												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	11,551,970	65.9%	65.9%	65.9%	5,974,526	65.9%	65.8%	65.9%	5,577,444	66.0%	65.9%	66.0%
Ages <45	1,122,627	81.3%	81.2%	81.4%	435,225	76.6%	76.5%	76.7%	687,402	84.3%	84.2%	84.4%
Ages 45-54	1,704,177	72.7%	72.6%	72.7%	775,208	67.2%	67.1%	67.3%	928,969	77.2%	77.1%	77.3%
Ages 55-64	2,795,570	69.3%	69.2%	69.3%	1,575,964	68.9%	68.8%	69.0%	1,219,606	69.8%	69.7%	69.8%
Ages 65-74	2,991,024	65.1%	65.0%	65.2%	1,749,593	67.7%	67.6%	67.8%	1,241,431	61.4%	61.3%	61.5%
Ages 75+	2,938,572	52.7%	52.6%	52.8%	1,438,536	55.7%	55.5%	55.8%	1,500,036	49.9%	49.8%	50.0%
Ages <65	5,622,374	72.7%	72.7%	72.8%	2,786,397	69.6%	69.6%	69.7%	2,835,977	75.8%	75.7%	75.9%
Ages 65+	5,929,596	59.1%	59.0%	59.2%	3,188,129	62.5%	62.4%	62.5%	2,741,467	55.2%	55.1%	55.3%

All Cancer Sites Combined												
White												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	9,711,886	66.1%	66.1%	66.2%	5,013,512	65.8%	65.7%	65.8%	4,698,374	66.5%	66.5%	66.6%
Ages <45	896,724	82.8%	82.7%	82.9%	352,743	78.3%	78.1%	78.4%	543,981	85.7%	85.6%	85.8%
Ages 45-54	1,367,680	73.9%	73.8%	74.0%	617,214	68.0%	67.9%	68.1%	750,466	78.7%	78.6%	78.8%
Ages 55-64	2,300,200	69.8%	69.7%	69.9%	1,285,794	69.0%	68.9%	69.1%	1,014,406	70.8%	70.7%	70.9%
Ages 65-74	2,545,043	65.2%	65.1%	65.3%	1,483,133	67.4%	67.3%	67.5%	1,061,910	62.2%	62.1%	62.3%
Ages 75+	2,602,239	53.0%	52.9%	53.1%	1,274,628	55.4%	55.2%	55.5%	1,327,611	50.7%	50.5%	50.8%
Ages <65	4,564,604	73.6%	73.6%	73.7%	2,255,751	70.2%	70.1%	70.3%	2,308,853	77.0%	76.9%	77.0%
Ages 65+	5,147,282	59.2%	59.1%	59.2%	2,757,761	62.0%	61.9%	62.1%	2,389,521	55.9%	55.8%	56.0%

All Cancer Sites Combined												
Black												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	1,309,965	60.6%	60.5%	60.7%	688,168	63.0%	62.9%	63.2%	621,797	58.0%	57.9%	58.2%
Ages <45	144,763	70.3%	70.0%	70.5%	53,166	63.6%	63.1%	64.0%	91,597	74.2%	73.9%	74.5%
Ages 45-54	244,374	63.3%	63.1%	63.5%	120,337	60.9%	60.6%	61.2%	124,037	65.6%	65.3%	66.0%
Ages 55-64	369,166	63.3%	63.1%	63.5%	220,873	66.0%	65.7%	66.2%	148,293	59.4%	59.1%	59.7%
Ages 65-74	320,185	61.0%	60.8%	61.3%	188,862	66.8%	66.5%	67.1%	131,323	52.9%	52.5%	53.2%
Ages 75+	231,477	45.8%	45.5%	46.2%	104,930	52.0%	51.5%	52.5%	126,547	40.8%	40.4%	41.2%
Ages <65	758,303	64.7%	64.5%	64.8%	394,376	64.1%	63.9%	64.2%	363,927	65.4%	65.2%	65.5%
Ages 65+	551,662	54.9%	54.7%	55.1%	293,792	61.7%	61.4%	62.0%	257,870	47.1%	46.8%	47.4%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 2. Five-Year Relative Survival*, Oral Cavity and Pharynx Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

Oral Cavity and Pharynx Cancer												
All Races												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	322,237	60.1%	59.9%	60.3%	224,886	58.9%	58.7%	59.2%	97,351	62.8%	62.4%	63.2%
Ages <45	26,977	77.6%	77.1%	78.2%	16,949	74.6%	73.9%	75.4%	10,028	82.7%	81.8%	83.5%
Ages 45-54	65,701	66.1%	65.7%	66.6%	49,485	64.7%	64.2%	65.2%	16,216	70.5%	69.7%	71.3%
Ages 55-64	92,923	61.2%	60.8%	61.6%	70,513	59.8%	59.3%	60.2%	22,410	65.5%	64.8%	66.3%
Ages 65-74	73,376	55.2%	54.7%	55.7%	51,458	53.5%	52.9%	54.0%	21,918	59.0%	58.2%	59.8%
Ages 75+	66,162	48.4%	47.7%	49.0%	38,420	47.3%	46.5%	48.1%	27,742	49.7%	48.8%	50.7%
Ages <65	184,451	65.6%	65.3%	65.9%	136,125	63.6%	63.3%	64.0%	48,326	71.0%	70.5%	71.5%
Ages 65+	138,809	52.1%	51.7%	52.4%	89,455	50.9%	50.4%	51.4%	49,354	54.0%	53.4%	54.6%

Oral Cavity and Pharynx Cancer												
White												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	274,741	61.5%	61.2%	61.7%	192,316	60.8%	60.5%	61.1%	82,425	63.0%	62.6%	63.4%
Ages <45	20,279	79.3%	78.7%	79.9%	12,939	76.7%	75.9%	77.5%	7,340	83.9%	83.0%	84.8%
Ages 45-54	53,839	68.9%	68.5%	69.4%	41,061	67.8%	67.3%	68.3%	12,778	72.5%	71.6%	73.4%
Ages 55-64	78,750	63.3%	62.8%	63.7%	60,029	62.1%	61.6%	62.6%	18,721	66.8%	66.0%	67.6%
Ages 65-74	64,014	56.7%	56.2%	57.2%	44,861	55.4%	54.8%	56.0%	19,153	59.5%	58.6%	60.4%
Ages 75+	60,423	48.9%	48.3%	49.6%	35,130	48.2%	47.3%	49.0%	25,293	49.9%	48.9%	50.9%
Ages <65	151,899	67.7%	67.4%	67.9%	113,334	66.1%	65.8%	66.4%	38,565	72.2%	71.7%	72.7%
Ages 65+	123,762	53.1%	52.7%	53.5%	79,600	52.4%	51.9%	52.9%	44,162	54.3%	53.6%	54.9%

Oral Cavity and Pharynx Cancer												
Black												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	32,912	44.2%	43.5%	44.8%	23,049	39.7%	38.9%	40.4%	9,863	54.6%	53.4%	55.8%
Ages <45	3,793	65.0%	63.3%	66.7%	2,213	57.8%	55.5%	60.1%	1,580	75.1%	72.6%	77.3%
Ages 45-54	8,485	45.0%	43.8%	46.2%	6,097	41.1%	39.6%	42.5%	2,388	55.2%	52.9%	57.4%
Ages 55-64	10,497	42.4%	41.3%	43.6%	7,899	39.3%	37.9%	40.6%	2,598	52.1%	49.7%	54.3%
Ages 65-74	6,705	37.4%	35.9%	38.9%	4,866	33.2%	31.5%	35.0%	1,839	48.0%	45.1%	50.8%
Ages 75+	3,677	34.9%	32.5%	37.3%	2,144	29.7%	26.7%	32.7%	1,533	41.8%	38.1%	45.5%
Ages <65	22,643	47.4%	46.7%	48.2%	16,119	42.7%	41.8%	43.6%	6,524	59.1%	57.8%	60.5%
Ages 65+	10,347	36.4%	35.1%	37.6%	6,989	32.1%	30.6%	33.6%	3,358	45.1%	42.8%	47.4%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 3. Five-Year Relative Survival*, Esophageal Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

Esophageal Cancer												
All Races												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	143,690	18.2%	18.0%	18.5%	111,792	18.1%	17.8%	18.4%	31,898	18.7%	18.2%	19.3%
Ages <45	3,863	22.4%	21.0%	23.9%	3,132	21.2%	19.7%	22.8%	731	27.5%	24.1%	31.1%
Ages 45-54	17,303	21.0%	20.3%	21.6%	14,315	20.3%	19.6%	21.0%	2,988	24.2%	22.5%	25.9%
Ages 55-64	37,503	20.1%	19.6%	20.6%	31,073	19.7%	19.2%	20.2%	6,430	22.1%	21.0%	23.3%
Ages 65-74	41,811	19.6%	19.1%	20.0%	33,086	19.1%	18.6%	19.6%	8,725	21.2%	20.2%	22.3%
Ages 75+	43,320	13.5%	13.0%	13.9%	30,270	13.6%	13.0%	14.1%	13,050	13.3%	12.5%	14.1%
Ages <65	58,648	20.5%	20.2%	20.9%	48,504	20.0%	19.6%	20.4%	10,144	23.1%	22.2%	24.1%
Ages 65+	85,081	16.6%	16.2%	16.9%	63,318	16.5%	16.2%	16.9%	21,763	16.6%	16.0%	17.2%

Esophageal Cancer												
White												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	123,087	18.9%	18.7%	19.2%	97,169	18.8%	18.5%	19.1%	25,918	19.4%	18.8%	20.0%
Ages <45	3,181	23.0%	21.4%	24.6%	2,668	21.5%	19.8%	23.3%	513	31.0%	26.6%	35.3%
Ages 45-54	13,935	22.5%	21.7%	23.3%	11,886	21.7%	20.9%	22.5%	2,049	27.3%	25.1%	29.5%
Ages 55-64	30,957	21.3%	20.8%	21.9%	26,148	20.8%	20.3%	21.4%	4,809	23.9%	22.5%	25.3%
Ages 65-74	36,127	20.3%	19.8%	20.8%	28,999	19.9%	19.3%	20.5%	7,128	21.9%	20.8%	23.1%
Ages 75+	38,983	13.7%	13.2%	14.2%	27,545	13.8%	13.2%	14.4%	11,438	13.4%	12.6%	14.3%
Ages <65	48,057	21.8%	21.4%	22.2%	40,689	21.2%	20.7%	21.6%	7,368	25.3%	24.2%	26.5%
Ages 65+	75,063	17.0%	16.6%	17.3%	56,507	17.0%	16.6%	17.4%	18,556	16.8%	16.2%	17.5%

Esophageal Cancer												
Black												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	16,903	11.9%	11.3%	12.5%	11,941	11.1%	10.4%	11.8%	4,962	13.8%	12.6%	15.0%
Ages <45	540	15.7%	12.5%	19.2%	355	14.8%	11.0%	19.1%	185	17.3%	11.9%	23.5%
Ages 45-54	2,905	12.5%	11.2%	13.9%	2,060	11.2%	9.7%	12.8%	845	15.7%	13.1%	18.6%
Ages 55-64	5,568	12.1%	11.1%	13.1%	4,170	11.4%	10.3%	12.6%	1,398	14.2%	12.1%	16.5%
Ages 65-74	4,633	12.2%	11.1%	13.4%	3,339	11.1%	9.8%	12.5%	1,294	15.1%	12.8%	17.5%
Ages 75+	3,269	9.8%	8.4%	11.4%	2,023	9.7%	7.9%	11.7%	1,246	10.0%	7.9%	12.5%
Ages <65	9,009	12.5%	11.7%	13.3%	6,583	11.5%	10.7%	12.4%	2,426	15.0%	13.4%	16.7%
Ages 65+	7,899	11.2%	10.3%	12.1%	5,361	10.6%	9.5%	11.7%	2,538	12.6%	11.0%	14.2%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 4. Five-Year Relative Survival*, Stomach Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

Stomach Cancer												
Age group	Male and female				All Races Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
	All Ages	202,224	29.5%	29.2%	29.7%	124,186	27.2%	26.9%	27.5%	78,038	33.0%	32.6%
Ages <45	11,862	37.3%	36.3%	38.2%	6,382	33.4%	32.2%	34.7%	5,480	41.8%	40.4%	43.2%
Ages 45-54	23,450	34.5%	33.8%	35.2%	14,911	31.2%	30.3%	32.0%	8,539	40.3%	39.2%	41.5%
Ages 55-64	39,649	32.4%	31.8%	32.9%	27,040	29.7%	29.1%	30.4%	12,609	38.1%	37.1%	39.1%
Ages 65-74	51,898	31.3%	30.8%	31.8%	34,167	28.6%	28.0%	29.2%	17,731	36.3%	35.5%	37.2%
Ages 75+	75,601	23.6%	23.1%	24.0%	41,826	21.7%	21.1%	22.3%	33,775	25.8%	25.1%	26.4%
Ages <65	74,887	33.8%	33.4%	34.2%	48,290	30.7%	30.2%	31.1%	26,597	39.6%	38.9%	40.2%
Ages 65+	127,420	26.8%	26.5%	27.1%	75,946	24.9%	24.5%	25.3%	51,474	29.5%	29.0%	30.0%

Stomach Cancer												
Age group	Male and female				White Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
	All Ages	152,856	28.2%	27.9%	28.5%	95,938	26.0%	25.7%	26.4%	56,918	31.9%	31.4%
Ages <45	8,091	36.6%	35.5%	37.8%	4,490	32.1%	30.6%	33.6%	3,601	42.4%	40.6%	44.1%
Ages 45-54	16,403	32.8%	32.0%	33.6%	10,685	29.3%	28.3%	30.3%	5,718	39.4%	37.9%	40.8%
Ages 55-64	29,073	30.9%	30.2%	31.5%	20,316	28.2%	27.5%	28.9%	8,757	36.9%	35.8%	38.1%
Ages 65-74	39,386	30.1%	29.5%	30.7%	26,540	27.7%	27.0%	28.3%	12,846	35.1%	34.1%	36.1%
Ages 75+	60,071	23.1%	22.6%	23.6%	34,007	21.3%	20.7%	22.0%	26,064	25.2%	24.4%	25.9%
Ages <65	53,519	32.3%	31.9%	32.8%	35,461	29.1%	28.5%	29.6%	18,058	38.8%	38.0%	39.6%
Ages 65+	99,400	25.9%	25.6%	26.3%	60,514	24.2%	23.7%	24.7%	38,886	28.5%	27.9%	29.1%

Stomach Cancer												
Age group	Male and female				Black Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
	All Ages	32,922	29.4%	28.8%	30.0%	18,713	26.3%	25.5%	27.1%	14,209	33.5%	32.6%
Ages <45	2,295	33.7%	31.6%	35.9%	1,174	30.5%	27.6%	33.4%	1,121	37.1%	34.0%	40.2%
Ages 45-54	4,721	34.9%	33.4%	36.4%	2,893	30.6%	28.7%	32.5%	1,828	41.7%	39.2%	44.2%
Ages 55-64	7,211	32.2%	30.9%	33.5%	4,619	28.7%	27.1%	30.3%	2,592	38.4%	36.2%	40.6%
Ages 65-74	8,332	30.8%	29.6%	32.1%	5,088	27.0%	25.4%	28.5%	3,244	36.8%	34.8%	38.8%
Ages 75+	10,409	22.5%	21.3%	23.7%	4,964	19.2%	17.5%	20.9%	5,445	25.3%	23.7%	27.0%
Ages <65	14,210	33.3%	32.4%	34.2%	8,678	29.6%	28.4%	30.7%	5,532	39.2%	37.8%	40.7%
Ages 65+	18,727	26.3%	25.5%	27.2%	10,045	23.3%	22.2%	24.5%	8,682	29.7%	28.5%	31.0%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 5. Five-Year Relative Survival*, Colon and Rectum Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

Colon and Rectum Cancer												
All Races												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	1,314,149	63.8%	63.7%	63.9%	670,470	63.3%	63.1%	63.5%	643,679	64.3%	64.2%	64.5%
Ages <45	65,180	68.6%	68.1%	69.0%	33,460	66.9%	66.3%	67.4%	31,720	70.3%	69.7%	70.9%
Ages 45-54	166,349	70.0%	69.7%	70.2%	90,367	68.3%	68.0%	68.7%	75,982	71.9%	71.5%	72.3%
Ages 55-64	262,090	67.5%	67.3%	67.7%	150,193	66.6%	66.3%	66.9%	111,897	68.8%	68.5%	69.1%
Ages 65-74	332,102	65.6%	65.3%	65.8%	182,641	64.7%	64.4%	64.9%	149,461	66.6%	66.3%	66.9%
Ages 75+	493,026	57.8%	57.6%	58.1%	216,442	57.0%	56.6%	57.3%	276,584	58.4%	58.1%	58.7%
Ages <65	492,507	68.5%	68.4%	68.7%	273,348	67.2%	67.0%	67.4%	219,159	70.1%	69.9%	70.3%
Ages 65+	823,020	61.0%	60.8%	61.1%	397,961	60.6%	60.3%	60.8%	425,059	61.3%	61.1%	61.6%

Colon and Rectum Cancer												
White												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	1,100,836	64.3%	64.2%	64.4%	565,332	63.8%	63.7%	64.0%	535,504	64.8%	64.6%	65.0%
Ages <45	50,078	69.6%	69.2%	70.1%	26,062	67.7%	67.0%	68.3%	24,016	71.7%	71.1%	72.4%
Ages 45-54	127,903	70.8%	70.5%	71.1%	71,102	69.2%	68.8%	69.6%	56,801	72.7%	72.3%	73.1%
Ages 55-64	209,232	68.1%	67.9%	68.4%	121,918	67.2%	66.9%	67.5%	87,314	69.5%	69.1%	69.8%
Ages 65-74	279,021	66.2%	65.9%	66.4%	155,097	65.3%	65.0%	65.6%	123,924	67.2%	66.9%	67.5%
Ages 75+	438,471	58.7%	58.4%	58.9%	193,367	57.8%	57.4%	58.1%	245,104	59.3%	59.0%	59.7%
Ages <65	386,338	69.2%	69.1%	69.4%	218,562	67.9%	67.7%	68.2%	167,776	70.9%	70.6%	71.1%
Ages 65+	715,639	61.6%	61.4%	61.8%	347,470	61.2%	60.9%	61.4%	368,169	62.0%	61.8%	62.2%

Colon and Rectum Cancer												
Black												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	157,813	57.8%	57.5%	58.2%	76,280	56.3%	55.8%	56.8%	81,533	59.3%	58.8%	59.7%
Ages <45	10,475	61.2%	60.2%	62.3%	5,037	59.0%	57.4%	60.5%	5,438	63.3%	61.8%	64.7%
Ages 45-54	28,339	63.4%	62.8%	64.1%	14,003	60.2%	59.2%	61.1%	14,336	66.6%	65.6%	67.4%
Ages 55-64	39,782	61.6%	61.0%	62.2%	21,027	59.8%	58.9%	60.6%	18,755	63.6%	62.8%	64.5%
Ages 65-74	39,313	58.7%	58.0%	59.3%	19,960	56.6%	55.6%	57.5%	19,353	60.7%	59.8%	61.6%
Ages 75+	40,465	48.0%	47.2%	48.8%	16,576	46.8%	45.5%	48.0%	23,889	48.8%	47.8%	49.8%
Ages <65	78,410	62.3%	61.8%	62.7%	39,947	59.9%	59.3%	60.4%	38,463	64.7%	64.1%	65.2%
Ages 65+	79,594	53.4%	52.9%	53.9%	36,442	52.3%	51.5%	53.0%	43,152	54.2%	53.6%	54.9%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, IL, ID, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 6. Five-Year Relative Survival*, Pancreatic Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

Pancreatic Cancer												
Age group	Male and female				All Races Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
	All Ages	345,608	8.5%	8.3%	8.6%	173,791	8.3%	8.2%	8.5%	171,817	8.6%	8.4%
Ages <45	9,257	30.0%	29.0%	31.1%	4,986	24.5%	23.2%	25.9%	4,271	36.5%	34.9%	38.1%
Ages 45-54	33,050	13.7%	13.3%	14.1%	19,449	12.3%	11.8%	12.8%	13,601	15.7%	15.0%	16.4%
Ages 55-64	72,632	9.9%	9.6%	10.1%	41,692	9.0%	8.7%	9.3%	30,940	11.0%	10.6%	11.5%
Ages 65-74	95,300	8.0%	7.8%	8.2%	50,499	7.9%	7.6%	8.2%	44,801	8.1%	7.8%	8.4%
Ages 75+	135,422	4.9%	4.8%	5.1%	57,195	5.2%	4.9%	5.4%	78,227	4.8%	4.5%	5.0%
Ages <65	114,917	12.7%	12.5%	12.9%	66,113	11.2%	10.9%	11.5%	48,804	14.7%	14.3%	15.0%
Ages 65+	230,709	6.2%	6.1%	6.4%	107,689	6.5%	6.3%	6.7%	123,020	6.0%	5.8%	6.2%

Pancreatic Cancer												
Age group	Male and female				White Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
	All Ages	290,573	8.2%	8.1%	8.3%	148,067	8.2%	8.0%	8.3%	142,506	8.2%	8.0%
Ages <45	7,046	29.3%	28.1%	30.5%	3,888	24.4%	22.9%	25.9%	3,158	35.4%	33.6%	37.3%
Ages 45-54	25,788	13.6%	13.1%	14.1%	15,410	12.3%	11.7%	12.9%	10,378	15.6%	14.8%	16.4%
Ages 55-64	59,026	9.7%	9.5%	10.0%	34,316	9.0%	8.7%	9.4%	24,710	10.7%	10.3%	11.2%
Ages 65-74	80,228	7.9%	7.7%	8.2%	43,406	7.8%	7.5%	8.2%	36,822	8.0%	7.7%	8.4%
Ages 75+	118,527	4.8%	4.7%	5.0%	51,070	5.0%	4.8%	5.3%	67,457	4.7%	4.4%	4.9%
Ages <65	91,843	12.4%	12.2%	12.7%	53,604	11.1%	10.8%	11.5%	38,239	14.2%	13.8%	14.6%
Ages 65+	198,746	6.1%	6.0%	6.2%	94,473	6.4%	6.1%	6.6%	104,273	5.9%	5.7%	6.1%

Pancreatic Cancer												
Age group	Male and female				Black Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
	All Ages	43,074	8.8%	8.5%	9.1%	19,854	8.1%	7.6%	8.6%	23,220	9.4%	8.9%
Ages <45	1,626	30.7%	28.3%	33.2%	780	22.2%	19.1%	25.6%	846	38.5%	34.9%	42.1%
Ages 45-54	5,947	12.3%	11.3%	13.3%	3,292	10.6%	9.4%	11.9%	2,655	14.3%	12.8%	15.9%
Ages 55-64	10,983	9.1%	8.4%	9.8%	5,962	7.7%	6.9%	8.6%	5,021	10.7%	9.7%	11.8%
Ages 65-74	11,789	7.4%	6.8%	8.1%	5,483	7.0%	6.2%	7.9%	6,306	7.8%	7.0%	8.7%
Ages 75+	12,737	4.9%	4.4%	5.5%	4,343	5.4%	4.5%	6.3%	8,394	4.7%	4.1%	5.4%
Ages <65	18,552	12.1%	11.6%	12.7%	10,031	9.9%	9.2%	10.6%	8,521	14.8%	13.9%	15.7%
Ages 65+	24,524	6.1%	5.7%	6.5%	9,824	6.3%	5.6%	6.9%	14,700	6.1%	5.6%	6.6%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

†Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 7. Five-Year Relative Survival*, Laryngeal Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

Laryngeal Cancer												
Age group	Male and female				All Races				Female			
	N	Relative Survival	95% LCI	95% UCI	Male				N	Relative Survival	95% LCI	95% UCI
					N	Relative Survival	95% LCI	95% UCI				
All Ages	116,059	59.5%	59.1%	59.8%	92,413	60.2%	59.8%	60.6%	23,646	56.5%	55.7%	57.3%
Ages <45	3,905	71.2%	69.6%	72.7%	2,739	69.7%	67.7%	71.5%	1,166	74.7%	71.8%	77.3%
Ages 45-54	18,860	62.6%	61.8%	63.4%	14,657	62.3%	61.4%	63.2%	4,203	63.7%	62.0%	65.4%
Ages 55-64	35,162	59.9%	59.3%	60.5%	28,224	59.9%	59.2%	60.6%	6,938	59.8%	58.4%	61.2%
Ages 65-74	33,771	58.2%	57.6%	58.9%	27,127	59.9%	59.1%	60.7%	6,644	51.7%	50.2%	53.1%
Ages 75+	24,635	55.7%	54.7%	56.7%	19,908	58.1%	56.9%	59.3%	4,727	46.2%	44.1%	48.3%
Ages <65	57,843	61.6%	61.1%	62.1%	45,550	61.3%	60.8%	61.9%	12,293	62.7%	61.7%	63.7%
Ages 65+	58,314	57.1%	56.6%	57.7%	46,952	59.1%	58.4%	59.7%	11,362	49.5%	48.2%	50.7%

Laryngeal Cancer												
Age group	Male and female				White				Female			
	N	Relative Survival	95% LCI	95% UCI	Male				N	Relative Survival	95% LCI	95% UCI
					N	Relative Survival	95% LCI	95% UCI				
All Ages	96,447	60.6%	60.2%	61.0%	76,660	61.5%	61.0%	61.9%	19,787	57.3%	56.4%	58.1%
Ages <45	3,169	74.0%	72.3%	75.6%	2,209	72.5%	70.4%	74.5%	960	77.5%	74.4%	80.2%
Ages 45-54	14,927	64.7%	63.9%	65.6%	11,584	64.3%	63.2%	65.2%	3,343	66.4%	64.6%	68.2%
Ages 55-64	28,439	61.5%	60.8%	62.2%	22,750	61.7%	60.9%	62.5%	5,689	60.6%	59.1%	62.1%
Ages 65-74	28,443	58.9%	58.1%	59.6%	22,778	60.6%	59.8%	61.5%	5,665	52.0%	50.4%	53.6%
Ages 75+	21,707	56.3%	55.2%	57.4%	17,548	58.8%	57.5%	60.0%	4,159	46.4%	44.2%	48.6%
Ages <65	46,468	63.5%	63.0%	64.0%	36,488	63.2%	62.7%	63.8%	9,980	64.3%	63.2%	65.4%
Ages 65+	50,067	57.7%	57.1%	58.3%	40,252	59.8%	59.0%	60.5%	9,815	49.7%	48.4%	51.0%

Laryngeal Cancer												
Age group	Male and female				Black				Female			
	N	Relative Survival	95% LCI	95% UCI	Male				N	Relative Survival	95% LCI	95% UCI
					N	Relative Survival	95% LCI	95% UCI				
All Ages	17,093	51.5%	50.5%	52.4%	13,645	51.6%	50.5%	52.7%	3,448	50.9%	48.9%	52.9%
Ages <45	634	54.4%	50.0%	58.6%	460	53.8%	48.6%	58.6%	174	56.2%	47.7%	63.8%
Ages 45-54	3,489	52.6%	50.7%	54.5%	2,704	52.8%	50.6%	54.9%	785	52.0%	47.9%	55.9%
Ages 55-64	5,997	50.7%	49.1%	52.2%	4,872	49.9%	48.1%	51.6%	1,125	54.3%	50.7%	57.7%
Ages 65-74	4,606	52.2%	50.2%	54.1%	3,728	53.0%	50.8%	55.2%	878	48.6%	44.3%	52.7%
Ages 75+	2,401	49.3%	46.0%	52.6%	1,912	50.9%	47.0%	54.6%	489	43.5%	37.1%	49.8%
Ages <65	10,104	51.7%	50.5%	52.9%	8,022	51.2%	49.9%	52.5%	2,082	53.6%	51.0%	56.0%
Ages 65+	6,999	51.2%	49.5%	52.8%	5,632	52.3%	50.4%	54.2%	1,367	46.7%	43.2%	50.2%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, IL, ID, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 8. Five-Year Relative Survival*, Liver Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

Liver Cancer												
Age group	Male and female				All Races				Female			
	N	Relative Survival	95% LCI	95% UCI	Male				N	Relative Survival	95% LCI	95% UCI
					N	Relative Survival	95% LCI	95% UCI				
All Ages	191,529	17.3%	17.1%	17.5%	136,932	16.8%	16.6%	17.0%	54,597	18.5%	18.1%	18.9%
Ages <45	8,732	36.7%	35.6%	37.8%	5,851	33.7%	32.4%	35.0%	2,881	42.9%	40.9%	44.9%
Ages 45-54	32,892	20.4%	19.9%	20.9%	26,588	19.1%	18.6%	19.6%	6,304	25.8%	24.6%	27.1%
Ages 55-64	58,723	19.6%	19.2%	20.0%	46,375	18.4%	17.9%	18.8%	12,348	23.9%	23.0%	24.8%
Ages 65-74	45,833	15.1%	14.7%	15.5%	31,650	14.3%	13.8%	14.8%	14,183	16.9%	16.2%	17.7%
Ages 75+	45,486	9.2%	8.8%	9.5%	26,565	9.2%	8.7%	9.8%	18,921	9.0%	8.4%	9.6%
Ages <65	100,297	21.5%	21.2%	21.8%	78,775	20.0%	19.6%	20.3%	21,522	27.2%	26.5%	27.9%
Ages 65+	91,285	12.2%	11.9%	12.5%	58,194	12.1%	11.7%	12.4%	33,091	12.5%	12.0%	13.0%

Liver Cancer												
Age group	Male and female				White				Female			
	N	Relative Survival	95% LCI	95% UCI	Male				N	Relative Survival	95% LCI	95% UCI
					N	Relative Survival	95% LCI	95% UCI				
All Ages	143,814	16.4%	16.2%	16.7%	102,557	16.0%	15.7%	16.3%	41,257	17.5%	17.0%	17.9%
Ages <45	5,487	38.9%	37.5%	40.3%	3,513	35.3%	33.6%	37.0%	1,974	45.3%	42.9%	47.8%
Ages 45-54	23,474	20.6%	20.0%	21.2%	19,089	19.4%	18.8%	20.0%	4,385	26.0%	24.5%	27.5%
Ages 55-64	41,904	19.4%	18.9%	19.9%	33,098	18.2%	17.7%	18.8%	8,806	23.6%	22.5%	24.7%
Ages 65-74	35,163	13.7%	13.2%	14.2%	24,482	13.0%	12.4%	13.5%	10,681	15.3%	14.5%	16.2%
Ages 75+	37,871	8.4%	8.0%	8.8%	22,432	8.4%	7.8%	9.0%	15,439	8.4%	7.7%	9.0%
Ages <65	70,837	21.5%	21.2%	21.9%	55,679	19.9%	19.5%	20.3%	15,158	27.3%	26.5%	28.1%
Ages 65+	73,009	11.0%	10.7%	11.3%	46,899	10.9%	10.5%	11.3%	26,110	11.3%	10.8%	11.8%

Liver Cancer												
Age group	Male and female				Black				Female			
	N	Relative Survival	95% LCI	95% UCI	Male				N	Relative Survival	95% LCI	95% UCI
					N	Relative Survival	95% LCI	95% UCI				
All Ages	28,085	14.6%	14.1%	15.1%	20,531	13.2%	12.6%	13.8%	7,554	18.4%	17.3%	19.5%
Ages <45	1,665	27.3%	24.9%	29.6%	1,136	24.3%	21.6%	27.0%	529	33.8%	29.3%	38.3%
Ages 45-54	5,981	14.0%	13.0%	15.0%	4,681	12.2%	11.1%	13.3%	1,300	20.7%	18.2%	23.2%
Ages 55-64	11,407	14.7%	13.9%	15.6%	9,101	13.3%	12.4%	14.3%	2,306	20.1%	18.0%	22.3%
Ages 65-74	5,504	12.8%	11.6%	14.1%	3,760	10.6%	9.2%	12.1%	1,744	16.9%	14.7%	19.3%
Ages 75+	3,554	10.1%	8.7%	11.7%	1,874	10.6%	8.6%	12.8%	1,680	9.6%	7.7%	11.8%
Ages <65	19,039	15.8%	15.2%	16.5%	14,907	14.0%	13.4%	14.8%	4,132	22.3%	20.8%	23.8%
Ages 65+	9,056	11.8%	10.8%	12.7%	5,632	10.6%	9.5%	11.9%	3,424	13.4%	11.9%	15.0%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 9. Five-Year Relative Survival*, Lung and Bronchus Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

Lung and Bronchus Cancer												
Age group	Male and female				All Races				Female			
	N	Relative Survival	95% LCI	95% UCI	Male				N	Relative Survival	95% LCI	95% UCI
					N	Relative Survival	95% LCI	95% UCI				
All Ages	1,872,295	18.7%	18.6%	18.8%	1,010,725	15.9%	15.8%	16.0%	861,570	22.0%	21.9%	22.1%
Ages <45	34,907	28.9%	28.4%	29.4%	16,799	25.1%	24.4%	25.8%	18,108	32.4%	31.7%	33.2%
Ages 45-54	170,679	21.9%	21.7%	22.1%	89,890	17.8%	17.5%	18.0%	80,789	26.6%	26.2%	26.9%
Ages 55-64	411,654	20.8%	20.7%	21.0%	229,945	17.4%	17.2%	17.5%	181,709	25.2%	25.0%	25.5%
Ages 65-74	615,319	19.8%	19.6%	19.9%	338,324	16.9%	16.7%	17.0%	276,995	23.3%	23.1%	23.5%
Ages 75+	649,996	14.7%	14.6%	14.8%	340,552	12.8%	12.6%	12.9%	309,444	16.7%	16.6%	16.9%
Ages <65	615,585	21.6%	21.5%	21.7%	335,901	17.9%	17.7%	18.0%	279,684	26.1%	25.9%	26.3%
Ages 65+	1,260,722	17.2%	17.1%	17.3%	676,687	14.9%	14.7%	15.0%	584,035	19.9%	19.8%	20.0%

Lung and Bronchus Cancer												
Age group	Male and female				White				Female			
	N	Relative Survival	95% LCI	95% UCI	Male				N	Relative Survival	95% LCI	95% UCI
					N	Relative Survival	95% LCI	95% UCI				
All Ages	1,620,929	18.8%	18.8%	18.9%	867,494	16.0%	15.9%	16.1%	753,435	22.1%	22.0%	22.2%
Ages <45	27,404	29.7%	29.1%	30.3%	13,038	25.6%	24.8%	26.4%	14,366	33.4%	32.5%	34.2%
Ages 45-54	135,493	22.5%	22.2%	22.7%	70,255	18.2%	17.9%	18.5%	65,238	27.1%	26.8%	27.5%
Ages 55-64	344,296	21.1%	21.0%	21.3%	189,465	17.5%	17.3%	17.7%	154,831	25.6%	25.3%	25.8%
Ages 65-74	538,384	20.0%	19.8%	20.1%	293,626	17.0%	16.9%	17.2%	244,758	23.5%	23.3%	23.7%
Ages 75+	584,480	14.8%	14.7%	14.9%	305,307	12.8%	12.7%	13.0%	279,173	16.9%	16.7%	17.1%
Ages <65	505,808	21.9%	21.8%	22.1%	272,161	18.1%	17.9%	18.2%	233,647	26.4%	26.2%	26.7%
Ages 65+	1,118,688	17.3%	17.2%	17.4%	596,952	14.9%	14.8%	15.1%	521,736	20.0%	19.9%	20.2%

Lung and Bronchus Cancer												
Age group	Male and female				Black				Female			
	N	Relative Survival	95% LCI	95% UCI	Male				N	Relative Survival	95% LCI	95% UCI
					N	Relative Survival	95% LCI	95% UCI				
All Ages	200,110	16.2%	16.0%	16.4%	114,380	13.9%	13.7%	14.2%	85,730	19.3%	18.9%	19.6%
Ages <45	5,692	23.0%	21.8%	24.1%	2,883	19.8%	18.3%	21.4%	2,809	26.1%	24.4%	27.9%
Ages 45-54	29,623	18.1%	17.6%	18.6%	16,685	14.7%	14.1%	15.3%	12,938	22.5%	21.7%	23.3%
Ages 55-64	55,883	17.4%	17.1%	17.8%	33,920	15.1%	14.7%	15.6%	21,963	21.0%	20.4%	21.6%
Ages 65-74	61,155	16.3%	16.0%	16.7%	35,643	13.9%	13.5%	14.4%	25,512	19.7%	19.1%	20.3%
Ages 75+	48,678	12.4%	12.0%	12.9%	25,719	10.9%	10.3%	11.4%	22,959	14.2%	13.5%	14.8%
Ages <65	90,965	18.0%	17.7%	18.3%	53,371	15.2%	14.9%	15.6%	37,594	21.9%	21.4%	22.4%
Ages 65+	109,511	14.6%	14.4%	14.9%	61,202	12.7%	12.3%	13.0%	48,309	17.1%	16.7%	17.5%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 10. Five-Year Relative Survival*, Melanoma of the Skin, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

Melanoma of the Skin												
All Races												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	544,640	89.4%	89.3%	89.6%	311,795	87.1%	86.9%	87.3%	232,845	92.4%	92.3%	92.6%
Ages <45	98,738	93.9%	93.7%	94.1%	38,963	90.5%	90.2%	90.8%	59,775	96.1%	95.9%	96.3%
Ages 45-54	96,159	91.2%	91.0%	91.4%	49,791	88.4%	88.1%	88.8%	46,368	94.2%	93.9%	94.5%
Ages 55-64	114,662	89.6%	89.3%	89.8%	70,657	87.8%	87.5%	88.2%	44,005	92.4%	92.0%	92.7%
Ages 65-74	111,986	88.4%	88.1%	88.8%	73,941	87.3%	86.9%	87.7%	38,045	90.5%	90.0%	91.0%
Ages 75+	127,997	83.7%	83.2%	84.2%	81,890	82.3%	81.6%	83.0%	46,107	85.9%	85.1%	86.7%
Ages <65	307,998	91.6%	91.4%	91.7%	158,498	88.8%	88.6%	89.0%	149,500	94.5%	94.4%	94.7%
Ages 65+	238,157	86.1%	85.8%	86.4%	154,429	84.9%	84.5%	85.3%	83,728	88.1%	87.6%	88.6%

Melanoma of the Skin												
White												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	517,765	89.1%	88.9%	89.2%	298,329	86.7%	86.5%	86.9%	219,436	92.2%	92.0%	92.4%
Ages <45	91,768	93.7%	93.5%	93.9%	36,277	90.1%	89.8%	90.5%	55,491	96.0%	95.8%	96.2%
Ages 45-54	90,601	90.9%	90.6%	91.1%	47,125	88.0%	87.6%	88.4%	43,476	94.0%	93.7%	94.3%
Ages 55-64	108,938	89.2%	89.0%	89.5%	67,452	87.5%	87.1%	87.8%	41,486	92.1%	91.7%	92.5%
Ages 65-74	107,475	88.1%	87.8%	88.4%	71,257	87.0%	86.5%	87.4%	36,218	90.3%	89.8%	90.8%
Ages 75+	123,818	83.2%	82.7%	83.7%	79,619	81.8%	81.1%	82.5%	44,199	85.5%	84.7%	86.3%
Ages <65	289,779	91.2%	91.1%	91.4%	149,961	88.4%	88.1%	88.6%	139,818	94.3%	94.2%	94.5%
Ages 65+	229,487	85.7%	85.4%	86.0%	149,492	84.5%	84.1%	84.9%	79,995	87.8%	87.3%	88.3%

Melanoma of the Skin												
Black												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	3,048	66.1%	63.7%	68.3%	1,321	59.5%	55.8%	63.1%	1,727	70.9%	67.9%	73.7%
Ages <45	532	75.8%	71.5%	79.6%	212	64.1%	56.3%	70.8%	320	83.5%	78.4%	87.4%
Ages 45-54	465	68.9%	63.7%	73.6%	210	62.4%	54.1%	69.6%	255	74.1%	67.2%	79.8%
Ages 55-64	629	65.3%	60.4%	69.7%	301	54.2%	46.9%	60.9%	328	75.5%	69.0%	80.8%
Ages 65-74	639	63.5%	58.1%	68.4%	289	61.9%	53.3%	69.3%	350	64.8%	57.7%	71.1%
Ages 75+	802	58.6%	52.3%	64.3%	319	55.7%	45.1%	65.1%	483	60.2%	52.4%	67.2%
Ages <65	1,616	70.0%	67.3%	72.6%	719	59.5%	55.1%	63.7%	897	78.4%	75.0%	81.3%
Ages 65+	1,435	60.9%	56.8%	64.8%	603	59.2%	52.5%	65.3%	832	62.1%	56.8%	66.9%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 11. Five-Year Relative Survival*, Female Breast Cancer, by Race, and Age Group — National Program of Cancer Registries[¶], 2001-2013.

Age group	Female Breast Cancer											
	All races				White				Black			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	1,896,726	88.8%	88.7%	88.9%	1,599,804	89.9%	89.8%	90.0%	213,859	79.4%	79.2%	79.6%
Ages <45	213,712	87.5%	87.4%	87.7%	163,289	89.2%	89.0%	89.3%	34,813	78.1%	77.6%	78.6%
Ages 45-54	406,121	89.5%	89.4%	89.7%	328,326	90.9%	90.8%	91.0%	54,492	80.0%	79.6%	80.4%
Ages 55-64	469,266	89.4%	89.3%	89.5%	393,814	90.4%	90.3%	90.6%	54,349	80.4%	79.9%	80.8%
Ages 65-74	417,094	89.7%	89.5%	89.8%	362,170	90.5%	90.4%	90.7%	40,467	81.2%	80.6%	81.8%
Ages 75+	406,386	87.1%	86.9%	87.4%	365,243	88.1%	87.8%	88.3%	32,009	75.5%	74.5%	76.4%
Ages <65	1,082,030	89.1%	89.0%	89.2%	880,008	90.4%	90.3%	90.5%	142,339	79.7%	79.5%	80.0%
Ages 65+	819,599	88.4%	88.3%	88.6%	723,960	89.3%	89.1%	89.4%	72,114	78.8%	78.2%	79.3%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

¶Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 12. Five-Year Relative Survival*, Cervical Cancer (Cervix Uteri), by Race, and Age Group — National Program of Cancer Registries[¶], 2001-2013.

Age group	Cervical Cancer (Cervix Uteri)											
	All races				White				Black			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	117,086	67.7%	67.4%	68.0%	88,890	69.0%	68.7%	69.4%	20,307	58.3%	57.5%	59.1%
Ages <45	45,419	80.1%	79.7%	80.5%	35,639	81.9%	81.4%	82.3%	6,772	68.6%	67.3%	69.8%
Ages 45-54	27,565	68.1%	67.5%	68.7%	20,708	69.5%	68.7%	70.2%	4,923	58.8%	57.3%	60.4%
Ages 55-64	20,362	60.5%	59.7%	61.3%	15,120	60.7%	59.8%	61.6%	3,748	54.7%	52.8%	56.5%
Ages 65-74	12,999	54.9%	53.9%	55.9%	9,548	55.0%	53.8%	56.2%	2,604	49.9%	47.5%	52.3%
Ages 75+	10,809	39.2%	37.8%	40.5%	7,916	38.3%	36.7%	39.8%	2,282	39.4%	36.4%	42.3%
Ages <65	93,300	72.4%	72.1%	72.7%	71,438	73.9%	73.6%	74.3%	15,429	62.2%	61.3%	63.0%
Ages 65+	23,799	48.0%	47.2%	48.8%	17,459	47.7%	46.7%	48.6%	4,883	45.1%	43.2%	46.9%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

¶Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 13. Five-Year Relative Survival*, Uterine Cancer (Corpus and Uterus, NOS,) by Race, and Age Group — National Program of Cancer Registries[¶], 2001-2013.

Age group	Uterine Cancer (Corpus and Uterus, NOS)											
	All races				White				Black			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	406,365	80.5%	80.3%	80.6%	345,807	82.6%	82.4%	82.8%	42,624	60.7%	60.1%	61.3%
Ages <45	28,059	89.8%	89.4%	90.2%	22,299	90.6%	90.2%	91.1%	3,279	82.2%	80.7%	83.7%
Ages 45-54	70,879	88.1%	87.8%	88.4%	60,298	89.4%	89.1%	89.7%	5,794	72.0%	70.7%	73.4%
Ages 55-64	130,323	84.2%	83.9%	84.4%	110,655	86.5%	86.3%	86.8%	13,870	63.7%	62.7%	64.7%
Ages 65-74	100,102	77.2%	76.8%	77.5%	84,628	80.2%	79.8%	80.5%	12,345	55.8%	54.7%	57.0%
Ages 75+	77,132	66.7%	66.1%	67.2%	68,026	69.2%	68.6%	69.8%	7,363	42.5%	40.8%	44.2%
Ages <65	229,218	86.2%	86.0%	86.3%	193,220	88.0%	87.8%	88.2%	22,934	68.7%	68.0%	69.4%
Ages 65+	177,195	72.7%	72.3%	73.0%	152,626	75.3%	75.0%	75.7%	19,698	51.0%	50.0%	52.0%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[¶]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 14. Five-Year Relative Survival*, Ovarian Cancer, by Race, and Age Group — National Program of Cancer Registries[¶], 2001-2013.

Age group	Ovarian Cancer											
	All races				White				Black			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	198,866	45.8%	45.6%	46.1%	172,353	45.9%	45.6%	46.2%	17,575	38.6%	37.8%	39.5%
Ages <45	22,869	75.4%	74.8%	76.0%	18,176	75.5%	74.8%	76.2%	2,755	72.5%	70.6%	74.3%
Ages 45-54	36,386	60.0%	59.4%	60.6%	30,676	61.1%	60.5%	61.7%	3,360	45.8%	43.8%	47.8%
Ages 55-64	46,325	49.4%	48.8%	49.9%	40,107	50.2%	49.6%	50.8%	4,107	36.0%	34.2%	37.8%
Ages 65-74	42,963	38.2%	37.6%	38.7%	37,809	39.2%	38.6%	39.8%	3,759	26.1%	24.4%	27.9%
Ages 75+	50,377	22.8%	22.3%	23.3%	45,635	23.0%	22.5%	23.5%	3,596	18.4%	16.6%	20.2%
Ages <65	105,552	58.8%	58.5%	59.2%	88,934	59.3%	58.9%	59.7%	10,221	49.6%	48.4%	50.7%
Ages 65+	93,329	30.0%	29.7%	30.4%	83,433	30.5%	30.1%	30.9%	7,355	22.4%	21.1%	23.6%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

¶Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 15. Five-Year Relative Survival*, Prostate Cancer, by Race, and Age Group — National Program of Cancer Registries[¶], 2001-2013.

Age group	Prostate Cancer											
	All races				White				Black			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	1,988,265	97.8%	97.8%	97.9%	1,595,712	97.9%	97.9%	98.0%	297,202	95.7%	95.5%	95.9%
Ages <45	11,729	95.6%	95.1%	96.0%	7,720	95.2%	94.5%	95.7%	3,440	96.3%	95.2%	97.1%
Ages 45-54	183,420	97.8%	97.6%	97.9%	134,380	97.9%	97.7%	98.0%	41,117	97.0%	96.7%	97.3%
Ages 55-64	611,723	98.9%	98.8%	99.0%	477,163	99.0%	99.0%	99.1%	107,033	97.6%	97.3%	97.8%
Ages 65-74	742,091	99.5%	99.3%	99.6%	604,637	99.6%	99.5%	99.7%	100,855	97.0%	96.7%	97.4%
Ages 75+	439,337	93.7%	93.5%	94.0%	371,844	93.8%	93.5%	94.1%	44,760	86.6%	85.7%	87.4%
Ages <65	806,868	98.6%	98.5%	98.6%	619,260	98.7%	98.7%	98.8%	151,589	97.4%	97.2%	97.6%
Ages 65+	1,181,408	97.4%	97.2%	97.5%	976,461	97.5%	97.3%	97.6%	145,615	93.9%	93.6%	94.3%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[¶]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 16. Five-Year Relative Survival*, Testicular Cancer, by Race, and Age Group — National Program of Cancer Registries[¶], 2001-2013.

Age group	Testicular Cancer											
	All races				White				Black			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	73,413	95.3%	95.1%	95.5%	67,659	95.5%	95.3%	95.7%	2,519	89.9%	88.3%	91.2%
Ages <45	58,034	96.0%	95.8%	96.1%	53,283	96.1%	95.9%	96.3%	1,974	91.4%	89.8%	92.7%
Ages 45-54	10,433	95.1%	94.6%	95.6%	9,753	95.3%	94.7%	95.8%	365	88.0%	83.2%	91.4%
Ages 55-64	3,294	91.4%	89.9%	92.7%	3,075	91.5%	89.9%	92.8%	122	84.2%	71.6%	91.5%
Ages 65-74	1,026	84.5%	80.7%	87.7%	969	85.0%	81.0%	88.2%	33	74.6%	50.4%	88.2%
Ages 75+	659	72.7%	65.2%	78.9%	612	74.5%	66.6%	80.9%	25	29.0%	7.7%	54.9%
Ages <65	71,729	95.6%	95.5%	95.8%	66,079	95.8%	95.6%	96.0%	2,461	90.6%	89.1%	91.9%
Ages 65+	1,685	80.2%	76.6%	83.3%	1,581	81.2%	77.5%	84.4%	58	58.3%	37.9%	74.1%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[¶]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 17. Five-Year Relative Survival*, Urinary Bladder Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

Urinary Bladder Cancer												
Age group	Male and female				All Races				Female			
	N	Relative Survival	95% LCI	95% UCI	Male				N	Relative Survival	95% LCI	95% UCI
					N	Relative Survival	95% LCI	95% UCI				
All Ages	625,425	75.6%	75.4%	75.7%	469,225	76.8%	76.6%	77.0%	156,200	72.0%	71.6%	72.3%
Ages <45	13,830	88.0%	87.4%	88.6%	9,769	89.2%	88.5%	89.9%	4,061	85.2%	84.0%	86.3%
Ages 45-54	45,193	83.8%	83.4%	84.2%	33,570	84.5%	84.1%	85.0%	11,623	81.7%	80.9%	82.5%
Ages 55-64	114,316	81.6%	81.4%	81.9%	87,476	82.0%	81.6%	82.3%	26,840	80.6%	80.0%	81.1%
Ages 65-74	182,598	77.4%	77.1%	77.7%	141,078	78.1%	77.7%	78.4%	41,520	75.1%	74.6%	75.7%
Ages 75+	272,127	68.7%	68.4%	69.0%	199,476	70.5%	70.1%	70.9%	72,651	63.8%	63.2%	64.4%
Ages <65	172,974	82.8%	82.5%	83.0%	130,514	83.2%	83.0%	83.5%	42,460	81.3%	80.9%	81.8%
Ages 65+	453,313	72.4%	72.2%	72.6%	339,411	73.9%	73.6%	74.1%	113,902	68.1%	67.7%	68.5%

Urinary Bladder Cancer												
Age group	Male and female				White				Female			
	N	Relative Survival	95% LCI	95% UCI	Male				N	Relative Survival	95% LCI	95% UCI
					N	Relative Survival	95% LCI	95% UCI				
All Ages	575,222	76.0%	75.8%	76.1%	434,566	76.9%	76.7%	77.1%	140,656	73.0%	72.7%	73.4%
Ages <45	11,997	89.1%	88.4%	89.7%	8,458	89.9%	89.2%	90.6%	3,539	87.0%	85.8%	88.2%
Ages 45-54	39,981	84.7%	84.3%	85.1%	29,797	85.0%	84.5%	85.5%	10,184	83.6%	82.8%	84.4%
Ages 55-64	103,570	82.2%	81.9%	82.5%	79,562	82.2%	81.9%	82.6%	24,008	81.9%	81.3%	82.5%
Ages 65-74	167,992	77.8%	77.5%	78.1%	130,716	78.2%	77.9%	78.6%	37,276	76.1%	75.6%	76.7%
Ages 75+	254,143	69.1%	68.8%	69.5%	188,057	70.7%	70.2%	71.1%	66,086	64.7%	64.1%	65.3%
Ages <65	155,210	83.4%	83.2%	83.6%	117,539	83.6%	83.3%	83.8%	37,671	82.9%	82.4%	83.3%
Ages 65+	420,821	72.8%	72.6%	73.0%	317,692	74.0%	73.7%	74.3%	103,129	69.0%	68.6%	69.5%

Urinary Bladder Cancer												
Age group	Male and female				Black				Female			
	N	Relative Survival	95% LCI	95% UCI	Male				N	Relative Survival	95% LCI	95% UCI
					N	Relative Survival	95% LCI	95% UCI				
All Ages	32,809	63.2%	62.4%	63.9%	21,587	67.9%	66.9%	68.8%	11,222	54.3%	53.0%	55.5%
Ages <45	1,024	71.8%	68.6%	74.7%	736	76.5%	72.9%	79.8%	288	59.6%	53.2%	65.4%
Ages 45-54	3,401	69.4%	67.5%	71.1%	2,407	73.8%	71.6%	75.8%	994	58.8%	55.2%	62.1%
Ages 55-64	7,078	68.6%	67.2%	70.0%	5,086	72.1%	70.4%	73.7%	1,992	60.1%	57.5%	62.6%
Ages 65-74	9,582	65.1%	63.7%	66.4%	6,509	68.7%	67.0%	70.4%	3,073	57.6%	55.3%	59.9%
Ages 75+	11,853	54.8%	53.2%	56.4%	6,934	59.6%	57.4%	61.8%	4,919	48.3%	46.0%	50.5%
Ages <65	11,478	69.2%	68.1%	70.2%	8,208	73.0%	71.8%	74.2%	3,270	59.6%	57.6%	61.6%
Ages 65+	21,366	59.6%	58.6%	60.7%	13,401	64.3%	62.9%	65.7%	7,965	52.0%	50.4%	53.6%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 18. Five-Year Relative Survival*, Kidney and Renal Pelvis Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

Kidney and Renal Pelvis Cancer												
All Races												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	439,827	71.2%	71.0%	71.3%	271,959	70.7%	70.5%	71.0%	167,868	71.8%	71.5%	72.1%
Ages <45	38,791	86.2%	85.8%	86.6%	22,767	84.6%	84.1%	85.2%	16,024	88.5%	87.9%	89.0%
Ages 45-54	70,314	78.6%	78.3%	79.0%	45,772	76.8%	76.4%	77.3%	24,542	82.0%	81.5%	82.6%
Ages 55-64	110,878	73.8%	73.5%	74.1%	72,556	72.4%	72.0%	72.8%	38,322	76.4%	75.8%	76.9%
Ages 65-74	115,783	69.7%	69.3%	70.0%	73,100	69.2%	68.7%	69.7%	42,683	70.4%	69.8%	70.9%
Ages 75+	105,494	58.5%	58.0%	58.9%	58,766	59.4%	58.7%	60.0%	46,728	57.3%	56.6%	58.0%
Ages <65	219,405	77.6%	77.4%	77.8%	140,700	75.9%	75.6%	76.1%	78,705	80.6%	80.3%	81.0%
Ages 65+	220,938	64.4%	64.1%	64.7%	131,627	64.9%	64.5%	65.3%	89,311	63.7%	63.2%	64.1%

Kidney and Renal Pelvis Cancer												
White												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	375,527	71.1%	70.9%	71.3%	233,347	70.7%	70.5%	71.0%	142,180	71.7%	71.4%	72.0%
Ages <45	30,860	87.5%	87.1%	87.9%	18,129	86.0%	85.5%	86.6%	12,731	89.7%	89.0%	90.2%
Ages 45-54	57,665	78.9%	78.5%	79.3%	37,598	76.9%	76.4%	77.4%	20,067	82.5%	81.9%	83.1%
Ages 55-64	92,965	73.9%	73.6%	74.3%	61,166	72.5%	72.1%	73.0%	31,799	76.6%	76.0%	77.1%
Ages 65-74	100,238	69.7%	69.3%	70.0%	63,813	69.2%	68.7%	69.7%	36,425	70.4%	69.8%	71.0%
Ages 75+	94,930	58.7%	58.2%	59.2%	53,427	59.7%	59.0%	60.4%	41,503	57.4%	56.7%	58.2%
Ages <65	181,056	77.9%	77.6%	78.1%	116,610	76.1%	75.8%	76.4%	64,446	81.0%	80.7%	81.4%
Ages 65+	194,885	64.4%	64.1%	64.7%	117,034	65.0%	64.6%	65.4%	77,851	63.6%	63.1%	64.1%

Kidney and Renal Pelvis Cancer												
Black												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	49,910	70.5%	69.9%	71.0%	29,573	69.8%	69.1%	70.5%	20,337	71.5%	70.7%	72.3%
Ages <45	5,893	78.7%	77.5%	79.9%	3,419	76.0%	74.3%	77.6%	2,474	82.5%	80.7%	84.1%
Ages 45-54	9,866	76.0%	75.0%	77.0%	6,326	74.6%	73.3%	75.9%	3,540	78.5%	76.8%	80.1%
Ages 55-64	14,160	72.2%	71.2%	73.1%	8,921	70.6%	69.3%	71.8%	5,239	74.8%	73.3%	76.3%
Ages 65-74	12,240	69.0%	67.8%	70.1%	7,203	68.4%	66.8%	70.0%	5,037	69.8%	68.0%	71.5%
Ages 75+	8,023	55.5%	53.6%	57.3%	3,902	55.8%	53.0%	58.5%	4,121	55.1%	52.7%	57.5%
Ages <65	29,788	74.8%	74.1%	75.4%	18,563	72.9%	72.1%	73.7%	11,225	77.8%	76.8%	78.7%
Ages 65+	20,212	63.8%	62.7%	64.8%	11,074	64.1%	62.7%	65.5%	9,138	63.3%	61.8%	64.7%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

†Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 19. Five-Year Relative Survival*, Brain and Other Nervous System Tumors, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

Brain and Other Nervous System Tumors												
Age group	Male and female				All Races				Female			
	N	Relative Survival	95% LCI	95% UCI	Male				N	Relative Survival	95% LCI	95% UCI
					N	Relative Survival	95% LCI	95% UCI				
All Ages	189,454	32.3%	32.0%	32.5%	104,632	30.9%	30.6%	31.3%	84,822	33.9%	33.5%	34.2%
Ages <45	56,946	68.2%	67.7%	68.6%	31,695	65.9%	65.4%	66.5%	25,251	70.9%	70.3%	71.6%
Ages 45-54	27,407	32.4%	31.8%	33.0%	16,016	29.2%	28.4%	30.0%	11,391	36.9%	35.9%	37.9%
Ages 55-64	36,333	17.5%	17.1%	18.0%	20,944	15.6%	15.0%	16.2%	15,389	20.2%	19.4%	20.9%
Ages 65-74	34,384	10.1%	9.7%	10.5%	19,204	9.0%	8.5%	9.5%	15,180	11.5%	10.9%	12.1%
Ages 75+	34,492	6.3%	6.0%	6.7%	16,830	5.7%	5.2%	6.2%	17,662	6.9%	6.4%	7.4%
Ages <65	120,596	45.2%	44.9%	45.5%	68,610	42.4%	42.0%	42.8%	51,986	48.8%	48.3%	49.3%
Ages 65+	68,870	8.2%	8.0%	8.5%	36,030	7.5%	7.1%	7.8%	32,840	9.0%	8.6%	9.4%

Brain and Other Nervous System Tumors												
Age group	Male and female				White				Female			
	N	Relative Survival	95% LCI	95% UCI	Male				N	Relative Survival	95% LCI	95% UCI
					N	Relative Survival	95% LCI	95% UCI				
All Ages	167,951	31.0%	30.7%	31.2%	93,171	29.9%	29.5%	30.2%	74,780	32.4%	32.0%	32.8%
Ages <45	47,435	68.7%	68.2%	69.1%	26,608	66.5%	65.8%	67.1%	20,827	71.5%	70.8%	72.1%
Ages 45-54	24,192	31.8%	31.2%	32.5%	14,207	28.6%	27.8%	29.5%	9,985	36.3%	35.3%	37.4%
Ages 55-64	32,841	16.9%	16.5%	17.4%	19,019	15.1%	14.5%	15.8%	13,822	19.4%	18.6%	20.1%
Ages 65-74	31,486	9.7%	9.3%	10.1%	17,655	8.7%	8.2%	9.2%	13,831	10.8%	10.2%	11.5%
Ages 75+	32,092	5.9%	5.5%	6.3%	15,735	5.4%	4.9%	5.9%	16,357	6.3%	5.9%	6.9%
Ages <65	104,388	44.3%	44.0%	44.6%	59,791	41.6%	41.2%	42.1%	44,597	47.8%	47.3%	48.3%
Ages 65+	63,572	7.8%	7.5%	8.0%	33,386	7.1%	6.8%	7.5%	30,186	8.4%	8.0%	8.8%

Brain and Other Nervous System Tumors												
Age group	Male and female				Black				Female			
	N	Relative Survival	95% LCI	95% UCI	Male				N	Relative Survival	95% LCI	95% UCI
					N	Relative Survival	95% LCI	95% UCI				
All Ages	14,178	38.9%	37.9%	39.8%	7,402	36.2%	35.0%	37.5%	6,776	41.7%	40.4%	43.0%
Ages <45	6,008	63.2%	61.8%	64.5%	3,147	60.5%	58.5%	62.3%	2,861	66.2%	64.2%	68.0%
Ages 45-54	2,203	32.5%	30.3%	34.7%	1,211	28.2%	25.3%	31.1%	992	37.6%	34.2%	41.0%
Ages 55-64	2,393	20.4%	18.5%	22.3%	1,323	17.3%	14.9%	19.9%	1,070	24.1%	21.2%	27.1%
Ages 65-74	1,968	12.4%	10.6%	14.3%	1,024	9.3%	7.2%	11.8%	944	15.6%	12.9%	18.5%
Ages 75+	1,617	10.8%	8.8%	13.2%	701	8.3%	5.5%	11.7%	916	12.7%	9.8%	15.9%
Ages <65	10,595	47.5%	46.4%	48.5%	5,679	43.9%	42.5%	45.4%	4,916	51.5%	50.0%	53.0%
Ages 65+	3,585	11.6%	10.2%	13.0%	1,725	8.8%	7.1%	10.7%	1,860	14.1%	12.1%	16.2%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 20. Five-Year Relative Survival*, Thyroid Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

Thyroid Cancer												
Age group	Male and female				All Races Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
	All Ages	333,730	96.8%	96.7%	96.9%	80,648	93.4%	93.1%	93.7%	253,082	97.8%	97.7%
Ages <45	123,438	99.4%	99.3%	99.5%	22,253	98.4%	98.1%	98.6%	101,185	99.6%	99.6%	99.7%
Ages 45-54	78,998	98.3%	98.1%	98.4%	17,988	95.6%	95.1%	96.0%	61,010	99.0%	98.9%	99.2%
Ages 55-64	63,955	96.2%	96.0%	96.5%	18,580	93.0%	92.4%	93.6%	45,375	97.6%	97.3%	97.8%
Ages 65-74	42,454	93.1%	92.7%	93.6%	13,798	89.5%	88.6%	90.4%	28,656	94.8%	94.3%	95.3%
Ages 75+	25,081	85.4%	84.5%	86.2%	8,090	81.1%	79.1%	82.9%	16,991	86.7%	85.8%	87.5%
Ages <65	266,280	98.3%	98.3%	98.4%	58,794	95.9%	95.6%	96.1%	207,486	99.0%	99.0%	99.1%
Ages 65+	67,505	90.3%	89.9%	90.8%	21,874	86.5%	85.5%	87.3%	45,631	92.1%	91.6%	92.7%

Thyroid Cancer												
Age group	Male and female				White Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
	All Ages	283,521	96.9%	96.7%	97.0%	71,027	93.5%	93.1%	93.8%	212,494	98.0%	97.9%
Ages <45	103,323	99.5%	99.4%	99.5%	19,012	98.5%	98.2%	98.7%	84,311	99.7%	99.6%	99.7%
Ages 45-54	66,920	98.3%	98.1%	98.5%	15,847	95.6%	95.0%	96.0%	51,073	99.1%	99.0%	99.3%
Ages 55-64	54,429	96.4%	96.1%	96.6%	16,466	93.0%	92.4%	93.6%	37,963	97.8%	97.5%	98.1%
Ages 65-74	36,655	93.4%	92.8%	93.8%	12,347	89.7%	88.7%	90.6%	24,308	95.2%	94.6%	95.7%
Ages 75+	22,367	86.2%	85.3%	87.0%	7,409	81.7%	79.6%	83.6%	14,958	87.5%	86.7%	88.2%
Ages <65	224,571	98.4%	98.3%	98.5%	51,300	95.9%	95.6%	96.1%	173,271	99.1%	99.0%	99.2%
Ages 65+	58,993	90.7%	90.2%	91.2%	19,743	86.7%	85.8%	87.7%	39,250	92.6%	92.1%	93.1%

Thyroid Cancer												
Age group	Male and female				Black Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
	All Ages	26,022	95.4%	94.9%	95.8%	4,666	91.2%	89.7%	92.4%	21,356	96.3%	95.8%
Ages <45	9,092	98.9%	98.5%	99.2%	1,285	96.5%	94.8%	97.7%	7,807	99.3%	98.9%	99.5%
Ages 45-54	6,424	97.2%	96.4%	97.8%	1,064	93.4%	91.0%	95.2%	5,360	97.9%	97.1%	98.5%
Ages 55-64	5,564	94.8%	93.6%	95.7%	1,138	91.0%	87.7%	93.5%	4,426	95.8%	94.6%	96.7%
Ages 65-74	3,376	90.5%	88.5%	92.2%	810	86.4%	81.9%	89.8%	2,566	91.5%	89.2%	93.4%
Ages 75+	1,579	78.0%	73.6%	81.8%	370	71.8%	62.8%	79.0%	1,209	79.9%	74.9%	84.0%
Ages <65	21,073	97.3%	97.0%	97.7%	3,487	93.9%	92.6%	95.1%	17,586	98.0%	97.6%	98.4%
Ages 65+	4,955	86.6%	84.6%	88.3%	1,180	81.9%	77.8%	85.3%	3,775	87.8%	85.7%	89.7%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

†Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 21. Five-Year Relative Survival*, Hodgkin Lymphoma, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

Hodgkin Lymphoma												
Age group	Male and female				All Races Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
	All Ages	79,056	83.3%	83.0%	83.6%	43,287	81.9%	81.5%	82.4%	35,769	84.9%	84.5%
Ages <45	46,719	93.1%	92.8%	93.3%	24,800	91.8%	91.4%	92.2%	21,919	94.5%	94.2%	94.9%
Ages 45-54	9,984	85.1%	84.2%	85.9%	6,244	83.1%	82.0%	84.2%	3,740	88.3%	87.0%	89.5%
Ages 55-64	8,225	74.7%	73.6%	75.9%	4,899	73.0%	71.4%	74.5%	3,326	77.3%	75.5%	78.9%
Ages 65-74	7,068	61.1%	59.7%	62.6%	3,963	58.9%	56.8%	60.8%	3,105	64.0%	61.9%	66.1%
Ages 75+	7,069	42.9%	41.2%	44.6%	3,383	41.1%	38.5%	43.6%	3,686	44.5%	42.1%	46.8%
Ages <65	64,921	89.6%	89.3%	89.9%	35,941	87.8%	87.4%	88.2%	28,980	91.8%	91.4%	92.2%
Ages 65+	14,136	52.3%	51.1%	53.4%	7,346	51.0%	49.4%	52.5%	6,790	53.6%	52.0%	55.2%

Hodgkin Lymphoma												
Age group	Male and female				White Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
	All Ages	65,958	83.3%	83.0%	83.7%	36,127	82.3%	81.8%	82.8%	29,831	84.5%	84.0%
Ages <45	37,986	93.9%	93.7%	94.2%	20,154	93.0%	92.6%	93.4%	17,832	95.0%	94.6%	95.4%
Ages 45-54	8,064	86.3%	85.4%	87.1%	5,059	84.7%	83.5%	85.8%	3,005	88.9%	87.5%	90.2%
Ages 55-64	6,961	75.8%	74.5%	77.0%	4,170	74.8%	73.1%	76.4%	2,791	77.3%	75.4%	79.1%
Ages 65-74	6,366	61.0%	59.4%	62.5%	3,583	58.7%	56.6%	60.8%	2,783	63.7%	61.5%	65.9%
Ages 75+	6,589	42.8%	41.0%	44.6%	3,163	40.5%	37.8%	43.1%	3,426	44.9%	42.4%	47.2%
Ages <65	53,005	90.5%	90.2%	90.8%	29,381	89.1%	88.7%	89.5%	23,624	92.2%	91.8%	92.6%
Ages 65+	12,954	52.0%	50.8%	53.1%	6,746	50.5%	48.8%	52.1%	6,208	53.5%	51.9%	55.2%

Hodgkin Lymphoma												
Age group	Male and female				Black Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
	All Ages	9,967	81.2%	80.2%	82.1%	5,406	77.4%	76.1%	78.7%	4,561	85.6%	84.3%
Ages <45	6,544	87.0%	86.0%	87.9%	3,477	83.4%	81.9%	84.8%	3,067	91.0%	89.8%	92.1%
Ages 45-54	1,611	77.8%	75.2%	80.1%	976	73.2%	69.8%	76.4%	635	84.6%	80.9%	87.7%
Ages 55-64	990	67.1%	63.3%	70.6%	559	60.7%	55.4%	65.5%	431	75.4%	69.8%	80.1%
Ages 65-74	515	62.3%	56.4%	67.6%	259	60.3%	51.7%	67.9%	256	64.3%	56.0%	71.5%
Ages 75+	308	43.5%	35.4%	51.2%	135	45.7%	32.7%	57.7%	173	40.6%	29.7%	51.2%
Ages <65	9,144	83.3%	82.4%	84.2%	5,012	79.0%	77.6%	80.3%	4,132	88.5%	87.3%	89.6%
Ages 65+	823	55.8%	50.9%	60.4%	394	56.5%	49.0%	63.2%	429	55.2%	48.6%	61.3%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 22. Five-Year Relative Survival*, Non-Hodgkin Lymphoma, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

Non-Hodgkin Lymphoma												
All Races												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	561,950	67.6%	67.4%	67.8%	301,557	65.7%	65.5%	65.9%	260,393	69.8%	69.6%	70.0%
Ages <45	63,057	79.0%	78.7%	79.4%	38,337	76.4%	76.0%	76.9%	24,720	83.1%	82.6%	83.6%
Ages 45-54	72,974	77.6%	77.3%	77.9%	42,169	74.2%	73.7%	74.7%	30,805	82.2%	81.7%	82.7%
Ages 55-64	112,393	74.7%	74.4%	75.0%	62,704	71.4%	71.0%	71.9%	49,689	78.7%	78.3%	79.2%
Ages 65-74	136,006	68.0%	67.6%	68.3%	73,056	65.0%	64.6%	65.5%	62,950	71.2%	70.8%	71.7%
Ages 75+	179,521	53.1%	52.7%	53.5%	86,396	50.8%	50.2%	51.4%	93,125	55.1%	54.6%	55.6%
Ages <65	247,780	76.7%	76.5%	76.9%	142,856	73.7%	73.4%	74.0%	104,924	80.8%	80.6%	81.1%
Ages 65+	314,860	59.8%	59.5%	60.0%	159,098	57.6%	57.2%	58.0%	155,762	61.8%	61.5%	62.2%

Non-Hodgkin Lymphoma												
White												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	492,298	67.9%	67.7%	68.1%	264,584	66.1%	65.8%	66.3%	227,714	70.0%	69.7%	70.2%
Ages <45	47,701	81.5%	81.2%	81.9%	29,415	78.7%	78.2%	79.2%	18,286	86.1%	85.5%	86.6%
Ages 45-54	60,041	79.4%	79.1%	79.8%	34,878	76.3%	75.8%	76.9%	25,163	83.7%	83.2%	84.2%
Ages 55-64	97,345	75.6%	75.2%	75.9%	54,595	72.5%	72.0%	72.9%	42,750	79.5%	79.0%	80.0%
Ages 65-74	122,205	68.4%	68.0%	68.7%	66,021	65.5%	65.0%	65.9%	56,184	71.7%	71.2%	72.2%
Ages 75+	166,806	53.2%	52.8%	53.6%	80,673	50.8%	50.2%	51.4%	86,133	55.3%	54.8%	55.8%
Ages <65	204,527	78.2%	78.0%	78.4%	118,575	75.3%	75.0%	75.6%	85,952	82.2%	81.9%	82.5%
Ages 65+	288,402	59.9%	59.6%	60.1%	146,370	57.7%	57.3%	58.1%	142,032	62.0%	61.6%	62.4%

Non-Hodgkin Lymphoma												
Black												
Age group	Male and female				Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
All Ages	45,627	61.4%	60.8%	62.0%	24,161	58.0%	57.2%	58.7%	21,466	65.3%	64.5%	66.1%
Ages <45	11,009	65.6%	64.6%	66.6%	6,410	63.0%	61.7%	64.3%	4,599	69.2%	67.8%	70.7%
Ages 45-54	9,249	63.7%	62.5%	64.8%	5,295	57.8%	56.2%	59.3%	3,954	71.6%	70.0%	73.2%
Ages 55-64	9,861	63.8%	62.6%	65.0%	5,351	58.6%	57.0%	60.3%	4,510	70.0%	68.3%	71.6%
Ages 65-74	8,403	60.1%	58.7%	61.5%	4,164	55.8%	53.7%	57.9%	4,239	64.2%	62.2%	66.0%
Ages 75+	7,243	48.1%	46.2%	49.9%	3,011	46.2%	43.1%	49.2%	4,232	49.4%	47.0%	51.7%
Ages <65	30,051	64.5%	63.9%	65.2%	17,025	60.2%	59.3%	61.0%	13,026	70.3%	69.4%	71.2%
Ages 65+	15,612	54.7%	53.6%	55.9%	7,157	51.9%	50.2%	53.6%	8,455	57.0%	55.5%	58.5%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

†Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 23. Five-Year Relative Survival*, Myeloma, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

Myeloma													
Age group	All Races												
	Male and female				Male				Female				
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	
All Ages	179,670	44.6%	44.3%	44.9%	98,069	44.9%	44.4%	45.3%	81,601	44.4%	43.9%	44.8%	
Ages <45	6,345	69.2%	67.8%	70.5%	3,738	67.9%	66.1%	69.6%	2,607	71.0%	69.0%	73.0%	
Ages 45-54	20,079	60.8%	60.0%	61.6%	11,330	58.6%	57.5%	59.7%	8,749	63.7%	62.5%	64.9%	
Ages 55-64	39,795	54.9%	54.3%	55.6%	22,638	54.8%	54.0%	55.6%	17,157	55.1%	54.2%	56.1%	
Ages 65-74	50,973	44.2%	43.6%	44.8%	28,635	43.5%	42.7%	44.2%	22,338	45.1%	44.2%	45.9%	
Ages 75+	62,689	28.5%	27.9%	29.0%	31,862	28.7%	27.9%	29.5%	30,827	28.2%	27.5%	28.9%	
Ages <65	66,133	58.2%	57.7%	58.7%	37,650	57.3%	56.7%	57.9%	28,483	59.4%	58.7%	60.0%	
Ages 65+	113,611	35.9%	35.5%	36.3%	60,471	36.1%	35.6%	36.7%	53,140	35.6%	35.1%	36.2%	

Myeloma													
Age group	White												
	Male and female				Male				Female				
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	
All Ages	137,044	43.7%	43.3%	44.0%	77,034	44.4%	43.9%	44.9%	60,010	42.8%	42.2%	43.3%	
Ages <45	4,061	69.0%	67.3%	70.6%	2,555	68.6%	66.4%	70.6%	1,506	69.7%	66.9%	72.2%	
Ages 45-54	13,697	62.4%	61.5%	63.4%	8,090	60.6%	59.3%	61.8%	5,607	65.1%	63.6%	66.5%	
Ages 55-64	28,659	55.1%	54.4%	55.8%	16,905	55.1%	54.1%	56.0%	11,754	55.2%	54.1%	56.3%	
Ages 65-74	39,084	44.1%	43.4%	44.7%	22,543	43.6%	42.7%	44.4%	16,541	44.7%	43.7%	45.7%	
Ages 75+	51,713	27.8%	27.2%	28.4%	27,053	28.6%	27.7%	29.4%	24,660	27.0%	26.2%	27.8%	
Ages <65	46,353	58.6%	58.1%	59.2%	27,505	58.1%	57.3%	58.8%	18,848	59.4%	58.6%	60.3%	
Ages 65+	90,752	35.2%	34.8%	35.6%	49,572	35.8%	35.2%	36.4%	41,180	34.5%	33.8%	35.1%	

Myeloma													
Age group	Black												
	Male and female				Male				Female				
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	
All Ages	36,277	46.8%	46.1%	47.5%	17,709	45.8%	44.8%	46.8%	18,568	47.8%	46.9%	48.8%	
Ages <45	1,942	68.2%	65.7%	70.6%	978	64.8%	61.1%	68.2%	964	71.7%	68.2%	74.9%	
Ages 45-54	5,523	56.1%	54.5%	57.7%	2,798	52.0%	49.7%	54.3%	2,725	60.3%	58.0%	62.5%	
Ages 55-64	9,553	53.3%	52.0%	54.6%	4,897	53.0%	51.2%	54.8%	4,656	53.6%	51.8%	55.4%	
Ages 65-74	10,064	43.9%	42.6%	45.2%	5,109	42.1%	40.2%	44.0%	4,955	45.7%	43.9%	47.6%	
Ages 75+	9,231	30.7%	29.2%	32.2%	3,946	29.1%	26.8%	31.5%	5,285	31.8%	29.9%	33.7%	
Ages <65	16,998	56.0%	55.1%	56.9%	8,663	54.0%	52.7%	55.3%	8,335	58.0%	56.7%	59.3%	
Ages 65+	19,290	37.9%	36.9%	38.9%	9,053	36.8%	35.4%	38.3%	10,237	38.8%	37.5%	40.2%	

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

†Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 24. Five-Year Relative Survival*, Leukemia, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

Leukemia												
Age group	Male and female				All Races Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
	All Ages	370,329	53.8%	53.6%	54.0%	212,941	54.2%	53.9%	54.5%	157,388	53.2%	52.9%
Ages <45	59,021	70.9%	70.5%	71.2%	33,480	70.8%	70.3%	71.3%	25,541	70.9%	70.3%	71.5%
Ages 45-54	38,130	65.9%	65.3%	66.4%	22,316	67.8%	67.1%	68.5%	15,814	63.1%	62.3%	63.9%
Ages 55-64	64,362	61.6%	61.1%	62.0%	39,415	62.0%	61.4%	62.6%	24,947	60.9%	60.2%	61.6%
Ages 65-74	84,183	51.3%	50.9%	51.8%	50,950	50.7%	50.1%	51.3%	33,233	52.2%	51.6%	52.9%
Ages 75+	124,995	37.1%	36.6%	37.5%	67,016	36.2%	35.7%	36.8%	57,979	37.9%	37.3%	38.5%
Ages <65	161,412	66.1%	65.9%	66.4%	95,146	66.6%	66.3%	67.0%	66,266	65.4%	65.0%	65.8%
Ages 65+	209,044	43.1%	42.8%	43.4%	117,871	42.9%	42.4%	43.3%	91,173	43.4%	43.0%	43.9%

Leukemia												
Age group	Male and female				White Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
	All Ages	323,547	53.7%	53.5%	54.0%	187,397	54.1%	53.8%	54.4%	136,150	53.3%	52.9%
Ages <45	47,053	71.9%	71.5%	72.4%	26,874	71.8%	71.3%	72.4%	20,179	72.1%	71.4%	72.7%
Ages 45-54	31,717	67.0%	66.4%	67.6%	18,676	69.0%	68.2%	69.7%	13,041	64.2%	63.2%	65.1%
Ages 55-64	55,578	62.2%	61.8%	62.7%	34,387	62.6%	61.9%	63.2%	21,191	61.7%	61.0%	62.5%
Ages 65-74	74,698	51.7%	51.2%	52.1%	45,621	50.9%	50.3%	51.5%	29,077	52.8%	52.1%	53.5%
Ages 75+	114,825	37.3%	36.9%	37.7%	62,052	36.4%	35.8%	37.0%	52,773	38.3%	37.7%	38.9%
Ages <65	134,260	66.9%	66.6%	67.2%	79,881	67.3%	67.0%	67.7%	54,379	66.3%	65.8%	66.7%
Ages 65+	189,402	43.3%	43.0%	43.6%	107,586	42.9%	42.5%	43.3%	81,816	43.7%	43.3%	44.2%

Leukemia												
Age group	Male and female				Black Male				Female			
	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI	N	Relative Survival	95% LCI	95% UCI
	All Ages	31,015	48.3%	47.6%	49.0%	16,569	49.1%	48.1%	50.0%	14,446	47.4%	46.4%
Ages <45	7,422	61.7%	60.5%	62.9%	4,072	61.5%	59.9%	63.1%	3,350	61.9%	60.1%	63.6%
Ages 45-54	4,304	54.6%	52.8%	56.3%	2,414	55.2%	52.8%	57.5%	1,890	53.9%	51.3%	56.4%
Ages 55-64	5,916	50.8%	49.3%	52.4%	3,297	51.2%	49.1%	53.4%	2,619	50.3%	48.0%	52.6%
Ages 65-74	6,470	42.8%	41.3%	44.4%	3,601	42.1%	39.9%	44.3%	2,869	43.7%	41.4%	46.0%
Ages 75+	6,936	29.4%	27.8%	31.1%	3,205	29.6%	27.1%	32.2%	3,731	29.2%	27.0%	31.4%
Ages <65	17,629	56.5%	55.7%	57.4%	9,774	56.7%	55.6%	57.9%	7,855	56.3%	55.0%	57.5%
Ages 65+	13,396	36.2%	35.0%	37.3%	6,800	36.5%	34.9%	38.2%	6,596	35.8%	34.2%	37.4%

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

†Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).